Aiphi Nguyen, PharmD, CEO

​Dr. Aiphi Nguyen has more than 17 years combined experience within the pharmaceutical and financial industry. She held various positions in marketing and sales at Bristol Myers Squibb in pediatrics with the responsibility of noticeable launch in orphan diseases or allergy field in France. Then she steered in the investment bank sector where she served as a business and financial analyst consultant engaged in various deals valuation mandates in the life sciences sector. Prior to Skymab, she had on her credit the creation of two successful companies (Etsi communication and dixhuit Production).

Dr. Aiphi Nguyen holds a Doctorate in Pharmacy of the University Claude Bernard, a MBA of IAE (Institut d’Administration des Entreprises from Sorbonne University), a master of science in Finance of ESCP Europe and Challenge Plus of HEC Startup Program.

Rémi Palmantier, PhD, CSO

Rémi joined Skymab as CSO in January 2021 after providing R&D strategic and management services to Biotech companies, including Skymab, in the field of cancer immunotherapy via his company ImmThera Consulting SAS. Previously, he served as CSO of Genticel, a French Biotech that developed an HPV-targeted therapeutic vaccine to treat oncogenic HPV-infection, which completed phase 2 clinical trial. Prior this position, he worked for 18 years at GSK-Biologicals in Belgium & Canada in R&D and one year in commercial strategy in Oncology.

He managed an international R&D team and major partnerships to build an R&D pipeline of experimental innovative immunotherapeutic projects from discovery to clinical stage in cancer and chronic diseases, which achieved proof of concept. He is a former NIH visiting fellow who worked on cancer research at NIEHS, USA after receiving his Ph.D. in Immunology from Laval University, Canada.

Caroline Mouline, PhD, R&D projects manager

Dr Caroline Mouline has more than 12 years experience in preclinical studies carried out on small molecules and therapeutic antibodies as Research Engineer. She conducted in-depth  research on small molecule derived from algae for the treatment of blood diseases with Kercells Biosciences. Prior joining Skymab, she gained extensive knowledge in immunotherapy in the laboratory of the University of Tours dedicated to therapeutics antibodies working on the induction of toloerogenic dendritic cells to treat transplant rejection.

Dr Caroline Mouline obtained her PhD in 2010 under the direction of Dr Jean-Claude Scimeca at the Nice University.

Peter Hudson, PhD, ADC expert advisor

Adj. Prof. Peter Hudson is a renowned scientist, ADC expert and inventor in the commercial development of immunotherapeutic products. Peter was Director of the Victorian Cancer Biologics (VCB) consortium in Australia and led the first-in-man clinical trial of a cancer-targeting diabody (2010-2018). Dr. Hudson is a prolific entrepreneur, having co-founded four immunotherapy companies Evogenix. (2001), Avipep (2005), CarTherics (2015), IsoClide Medical (2017) and has been an advisor to many international biotechnology companies including Affitech, ArGenX, Merus, CSL and Selexis.

Peter is currently an Adjunct Professor at the University of Queensland and formerly led large research teams as Chief Research Scientist in CSIRO (Australia’s premier science agency, 1984-2007) and as Scientific Director of the Cooperative Research Centre (CRC) for Diagnostics (1992-2007) and as BDM in the CRC for Mental Health (2009-2012). Peter earned his Ph.D. from the University of Cambridge (UK, 1980) for research at the renowned MRC Laboratory of Molecular Biology. He was later elected to the Australian Academy of Technological Sciences and has been awarded the Boehringer, AMRAD and CSIRO Chairman’s Medals.